Relief Therapeutics Holding AG (RLFTF)

[nelskof]

What specific questions do you have?

The company is going 'all-in' with the interim review at the 102nd patient that was enrolled 9/30. The data will be available to the board after 10/28.

It's very similar to the other company you are with in that they want to file an EUA based on 2b data. That will open the world to the drug.

It's really simple as that. If that data is overwhelming then it's all systems go. If it's not, then shut it down.

You can look to studies done in Brazil that backs the science, similar to the UT Dallas studies you should be familiar with on other drug.

Anything else?

Should have mentioned they already filed for EUA for critical patients based on the science and Expanded Access Protocol patients. We're still waiting to hear about that one.